BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

17 4 2024 04:30:39 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

05 4 2024 09:45:07 提供 NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

04 4 2024 15:51:53 提供 NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 4 2024 09:45:12 提供 NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 4 2024 07:00:23 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

02 4 2024 12:00:22 提供 NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

25 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

14 3 2024 13:48:51 提供 NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 3 2024 07:01:47 提供 Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

26 2 2024 07:00:05 提供 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

23 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

21 2 2024 16:01:58 提供 Nasdaq GlobeNewswire

BioCryst Launches ORLADEYO® (berotralstat) in Italy

19 2 2024 07:54:52 提供 Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

12 2 2024 07:00:53 提供 Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

05 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 2 2024 07:00:48 提供 Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

05 1 2024 16:01:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 1 2024 16:01:59 提供 Nasdaq GlobeNewswire

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 07:00:50 提供 Nasdaq GlobeNewswire

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

19 12 2023 07:00:00 提供 Nasdaq GlobeNewswire